The S-1 was not a dilutive or toxic financing. Maybe, a little education is in order. The term "dilutive financing" refers to convertible notes that have no specific exercise price or "floor" and is considered floorless. This means the funding conversion price is set at a set discount to market and means that regardless of how low the bid price of the stock may go the funder can exercise at a discount to market even if the stock drops down to .0001 bid. This can cause an OTC company with a 50 million share float go to a billion share float with the blink of an eye.
The S-1 that was done was set at a relatively small discount to market and all the shares for the $3 million were sold at .15 cents. Was there minor dilution? Of course, because they sold shares to raise capital, but it was not what anyone would consider to be a dilutive or toxic event.
News 
Market Data 
Discover 
AI
